Skip to main content

PLEASE NOTE: For everyone’s safety, Fasken recommends anyone on-site at our Canadian offices be familiar with the COVID-19 recommendations in place which may include one or more of the following: social distancing, hand sanitizing, wearing a mask in common areas and proof of full vaccination. These measures apply to lawyers, staff, clients, service providers and other visitors.

Client Work

DRAXIS Health completes sale to Jubilant Organosys for US$255 million

Fasken
Reading Time 1 minute read Subscribe

Overview

Client

DRAXIS Health

On May 28, 2008, Montreal-based pharmaceutical firm DRAXIS Health Inc. ("DRAXIS") (TSX: DAX) (NASDAQ: DRAX) announced the completion of a statutory arrangement pursuant to which all of the common shares of DRAXIS were acquired by an indirect wholly-owned subsidiary of India-based Jubilant Organosys Ltd. for US$6.00 per common share for a total value of approximately US$255 million. Jonathan Levin and Daniel Batista of Fasken Martineau advised the Special Committee of DRAXIS in connection with the transaction.

Team

    Subscribe

    Receive email updates from our team

    Subscribe